Reports Q2 revenue $21.2M, consensus $20.45M. “We are pleased with our second quarter results, which reflect our successful commercial execution as we accelerate adoption of the Ceribell (CBLL) System across new and existing accounts,” said co-founder and CEO Jane Chao. “As we look to the second half of 2025, we believe we are well-positioned to drive continued growth and propel key strategies to reach more patients, advance our pipeline, and reinforce our category leadership while establishing EEG as a new vital sign.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBLL:
- Ceribell, Inc.: Positioned for Growth with Strong Revenue Projections and Market Expansion Opportunities
- Ceribell, Inc.’s Strategic Positioning and Patent Strength Justify Buy Rating
- Ceribell Files Patent Infringement Complaints Against Natus
- Ceribell files complaints against Natus Medical, alleges patent infringement
- Ceribell initiated with a Buy at BTIG